Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2016

01-03-2016 | Review Article

Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography

Authors: Hitoshi Maruyama, Gamal Shiha, Osamu Yokosuka, Ashish Kumar, Barjesh Chander Sharma, Alaa Ibrahim, Vivek Saraswat, Cosmas Rinaldi A. Lesmana, Masao Omata

Published in: Hepatology International | Issue 2/2016

Login to get access

Abstract

Portal hypertension and hepatic fibrosis are key pathophysiologies with major manifestations in cirrhosis. Although the degree of portal pressure and hepatic fibrosis are pivotal parameters, both are determined using invasive procedures. Ultrasound (US) is a simple and non-invasive technique that is available for use worldwide in the abdominal field. Because of its safety and easy of use, contrast-enhanced US is one of the most frequently used tools in the management of liver tumors for the detection and characterization of lesions, assessment of malignancy grade, and evaluation of therapeutic effects. This wide range of applications drives the practical use of contrast-enhanced US for evaluation of the severity of portal hypertension and hepatic fibrosis. The present article reviews the recent progress in contrast-enhanced US for the assessment of portal hypertension and hepatic fibrosis.
Literature
1.
Goyal N, Jain N, Rachapalli V, Cochlin DL, Robinson M. Non-invasive evaluation of liver cirrhosis using ultrasound. Clin Radiol 2009;64:1056–1066.CrossRefPubMed
2.
Baik SK. Haemodynamic evaluation by Doppler ultrasonography in patients with portal hypertension: a review. Liver Int 2010;30:1403–1413.CrossRefPubMed
3.
Soresi M, Giannitrapani L, Cervello M, Licata A, Montalto G. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol 2014;28(20):18131–18150.CrossRef
4.
5.
Van Beers BE, Daire JL, Garteiser P. New imaging techniques for liver diseases. J Hepatol 2015;62:690–700.CrossRefPubMed
6.
7.
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver—update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013;39:187–210.CrossRefPubMed
8.
Bouakaz A, de Jong N. WFUMB safety symposium on echo-contrast agents: nature and types of ultrasound contrast agents. Ultrasound Med Biol 2007;33:187–196.CrossRefPubMed
9.
Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008;48:848–857.CrossRefPubMed
10.
Maruyama H, Ishibashi H, Takahashi M, et al. Effect of signal intensity from the accumulated microbubbles in the liver for differentiation of idiopathic portal hypertension from liver cirrhosis. Radiology 2009;252:587–594.CrossRefPubMed
11.
12.
Cobbold JF, Patel D, Fitzpatrick JA, Patel N, Crossey MM, Abdalla MS, Goldin RD, Vennart W, Thomas HC, Taylor-Robinson SD. Accuracy and reliability of microbubble ultrasound measurements for the non-invasive assessment of hepatic fibrosis in chronic hepatitis C. Hepatol Res 2012;42:515–522.CrossRefPubMed
13.
Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, Urbank A, Butler-Barnes J, Patel N. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999;353:1579–1583.CrossRefPubMed
14.
Sugimoto H, Kaneko T, Hirota M, Tezel E, Nakao A. Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intrahepatic hemodynamic changes accompanying cirrhosis. J Hepatol 2002;37:578–583.CrossRefPubMed
15.
Staub F, Tournoux-Facon C, Roumy J, Chaigneau C, Morichaut-Beauchant M, Levillain P, et al. Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring. Eur Radiol 2009;19:1991–1997.CrossRefPubMed
16.
Li N, Ding H, Fan P, et al. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography. Ultrasound Med Biol 2010;36:1066–1075.CrossRefPubMed
17.
Tang A, Kim TK, Heathcote J, et al. Does hepatic vein transit time performed with contrast-enhanced ultrasound predict the severity of hepatic fibrosis? Ultrasound Med Biol 2011;37:1963–1969.CrossRefPubMed
18.
Cobbold JF, Crossey MME, Colman P, et al. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Viral Hepat 2010;17:537–545.CrossRefPubMed
19.
Ridolfi F, Abbattista T, Marini F, et al. Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C. Dig Liver Dis 2007;39:929–935.CrossRefPubMed
20.
Lim AK, Patel N, Eckersley RJ, Goldin RD, Thomas HC, Cosgrove DO, et al. Hepatic vein transit time of SonoVue: a comparative study with Levovist. Radiology 2006;240:130–135.CrossRefPubMed
21.
Orlacchio A, Bolacchi F, Petrella MC, et al. Liver contrast enhanced ultrasound perfusion imaging in the evaluation of chronic hepatitis C fibrosis: preliminary results. Ultrasound Med Biol 2011;37:1–6.CrossRefPubMed
22.
Ishibashi H, Maruyama H, Takahashi M, et al. Assessment of hepatic fibrosis by analysis of the dynamic behavior of microbubbles during contrast ultrasonography. Liver Int 2010;30:1355–1363.CrossRefPubMed
23.
Tawada A, Maruyama H, Kamezaki H, et al. Magnitude of contrast-enhanced ultrasonography as a noninvasive predictor for hepatic fibrosis: comparison with liver stiffness measurement and serum-based models. Hepatol Int 2013;7:749–757.CrossRefPubMed
24.
Ishibashi H, Maruyama H, Takahashi M, et al. Demonstration of intrahepatic accumulated microbubble on ultrasound represents the grade of hepatic fibrosis. Eur Radiol 2012;22:1083–1090.CrossRefPubMedPubMedCentral
25.
Maruyama H, Shimada T, Ishibashi H, Takahashi M, Kamesaki H, Yokosuka O. Delayed periportal enhancement: a characteristic finding on contrast ultrasound in idiopathic portal hypertension. Hepatol Int 2012;6:511–519.CrossRefPubMed
26.
Maruyama H, Okugawa H, Kobayashi S, Yoshizumi H, Takahashi M, Ishibashi H, Yokosuka O. Non-invasive portography: a microbubble-induced three-dimensional sonogram for discriminating idiopathic portal hypertension from cirrhosis. Br J Radiol 2012;85:587–595.CrossRefPubMedPubMedCentral
27.
Zhang CX, Hu J, Hu KW, Zhang C, Wang L, Xu JM. Noninvasive analysis of portal pressure by contrast-enhanced sonography in patients with cirrhosis. J Ultrasound Med 2011;30:205–211.PubMed
28.
Kim MY, Suk KT, Baik SK, Kim HA, Kim YJ, Cha SH, Kwak HR, et al. Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology 2012;56:1053–1062.CrossRefPubMed
29.
Jeong WK, Kim TY, Sohn JH, Kim Y, Kim J. Severe portal hypertension in cirrhosis: evaluation of perfusion parameters with contrast-enhanced ultrasonography. PLoS ONE 2015;10:e0121601.CrossRefPubMedPubMedCentral
30.
Furuichi Y, Moriyasu F, Sugimoto K, Taira J, Sano T, Miyata Y, Sofuni A, Itoi T, Nakamura I, Imai Y. Obliteration of gastric varices improves the arrival time of ultrasound contrast agents in hepatic artery and vein. J Gastroenterol Hepatol 2013;28:1526–1531.CrossRefPubMed
31.
Berzigotti A, Nicolau C, Bellot P, et al. Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. J Hepatol 2011;55:307–314.CrossRefPubMed
32.
Qu EZ, Zhang YC, Li ZY, Liu Y, Wang JR. Contrast-enhanced sonography for quantitative assessment of portal hypertension in patients with liver cirrhosis. J Ultrasound Med 2014;33:1971–1977.CrossRefPubMed
33.
Shimada T, Maruyama H, Kondo T, Sekimoto T, Takahashi M, Yokosuka O. Impact of splenic circulation: non-invasive microbubble-based assessment of portal hemodynamics. Eur Radiol 2015;25:812–820.CrossRefPubMed
34.
Dave JK, Halldorsdottir VG, Eisenbrey JR, Merton DA, Liu JB, Zhou JH, Wang HK, Park S, Dianis S, Chalek CL, Lin F, Thomenius KE, Brown DB, Forsberg F. Investigating the efficacy of subharmonic aided pressure estimation for portal vein pressures and portal hypertension monitoring. Ultrasound Med Biol 2012;38:1784–1798.CrossRefPubMedPubMedCentral
35.
Eisenbrey JR, Dave JK, Halldorsdottir VG, et al. Chronic liver disease: noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient. Radiology 2013;268:581–588.CrossRefPubMedPubMedCentral
36.
Micol C, Marsot J, Boublay N, et al. Contrast-enhanced ultrasound: a new method for TIPS follow-up. Abdom Imaging 2012;37:252–260.CrossRefPubMed
37.
Maruyama H, Ishibashi H, Takahashi M, Shimada T, Kamesaki H, Yokosuka O. Prediction of the therapeutic effects of anticoagulation for recent portal vein thrombosis: a novel approach with contrast-enhanced ultrasound. Abdom Imaging 2012;37:431–438.CrossRefPubMed
38.
Maruyama H, Takahashi M, Shimada T, Yokosuka O. Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding. Scand J Gastroenterol 2012;47:686–691.CrossRefPubMed
39.
Kuroda T, Hirooka M, Koizumi M, et al. Pancreatic congestion in liver cirrhosis correlates with impaired insulin secretion. J Gastroenterol 2015;50:683–693.CrossRefPubMed
40.
Sekimoto T, Maruyama H, Kondo T, Shimada T, Kiyono S, Yokosuka O. Potential stagnation in the splanchnic hemodynamics demonstrated by the dynamic microbubble in chronic liver disease. J Gastroenterol Hepatol 2015;30:1001–1008.CrossRefPubMed
41.
Sekimoto T, Maruyama H, Kiyono S, Kondo T, Shimada T, Ishibashi H, Takahashi M, Yokosuka O, Yamaguchi T. Hepatic filling rate by a microbubble agent: a novel predictor of long-term outcomes in patients with cirrhosis. Ultrasound Med Biol 2014;40:2082–2088.CrossRefPubMed
Metadata
Title
Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography
Authors
Hitoshi Maruyama
Gamal Shiha
Osamu Yokosuka
Ashish Kumar
Barjesh Chander Sharma
Alaa Ibrahim
Vivek Saraswat
Cosmas Rinaldi A. Lesmana
Masao Omata
Publication date
01-03-2016
Publisher
Springer India
Published in
Hepatology International / Issue 2/2016
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-015-9670-9

Other articles of this Issue 2/2016

Hepatology International 2/2016 Go to the issue

Original Article

Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment

Original Article

The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool

Original Article

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study

Editorial

Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense

Review Article

Advances in therapeutics for chronic hepatitis B

Original Article

Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits